➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Merck
Johnson and Johnson
McKesson
AstraZeneca
Express Scripts
Boehringer Ingelheim

Last Updated: September 20, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for CC-486

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug CC-486?

CC-486 is an investigational drug.

There have been 20 clinical trials for CC-486. The most recent clinical trial was a Phase 1 trial, which was initiated on June 14th 2019.

The most common disease conditions in clinical trials are Lymphoma, Myelodysplastic Syndromes, and Preleukemia. The leading clinical trial sponsors are Celgene Corporation, Celgene, and Kirby Institute.

There are seven US patents protecting this investigational drug and one hundred and thirty-three international patents.

Recent Clinical Trials for CC-486
TitleSponsorPhase
A Study of Lenalidomide and CC-486 With Radiation Therapy in Patients With PlasmacytomaMemorial Sloan Kettering Cancer CenterPhase 2
Double-Blind, Phase 3, Randomised Study of Oral Azacitidine vs Placebo Maintenance in AML or MDS Patients After Allo-SCTUniversity of BirminghamPhase 3
Oral Azacitidine Plus Salvage Chemotherapy in Relapsed/Refractory Diffuse Large B Cell LymphomaCelgene CorporationPhase 1

See all CC-486 clinical trials

Clinical Trial Summary for CC-486

Top disease conditions for CC-486
Top clinical trial sponsors for CC-486

See all CC-486 clinical trials

US Patents for CC-486

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
CC-486   Start Trial Tricyclic inhibitors of poly(ADP-ribose) polymerases Agouron Pharmaceuticals, Inc. (San Diego, CA)   Start Trial
CC-486   Start Trial Therapeutic compounds Cancer Research Technology Limited (London, GB) Pfizer, Inc. (New York, NY)   Start Trial
CC-486   Start Trial Therapeutic compounds Cancer Research Technology Limited (London, GB) Pfizer (New York, NY)   Start Trial
CC-486   Start Trial Therapeutic kinase modulators Cylene Pharmaceuticals, Inc. (San Diego, CA)   Start Trial
CC-486   Start Trial Fused tricyclic compounds as serine-threonine protein kinase and PARP modulators Cylene Pharmaceuticals, Inc. (San Diego, CA)   Start Trial
CC-486   Start Trial Fused tricyclic compounds as serine-threonine protein kinase and PARP modulators SENHWA BIOSCIENCES, INC. (New Taipei, TW)   Start Trial
CC-486   Start Trial Crystalline forms of quinolone analogs and their salts SENHWA BIOSCIENCES, INC. (New Taipei, TW)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for CC-486

Drugname Country Document Number Estimated Expiration Related US Patent
CC-486 African Regional IP Organization (ARIPO) 1553 2019-08-31   Start Trial
CC-486 Argentina 035162 2019-08-31   Start Trial
CC-486 Austria 287406 2019-08-31   Start Trial
CC-486 Australia 7338900 2019-08-31   Start Trial
CC-486 Australia 781826 2019-08-31   Start Trial
CC-486 Bulgaria 106562 2019-08-31   Start Trial
CC-486 Brazil 0015051 2019-08-31   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Johnson and Johnson
McKesson
AstraZeneca
Express Scripts
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.